Biopharmaceutical Manufacturing Facility
Early partnering through design-assist offers the opportunity to provide input into the project schedule, logistics planning, long-lead procurements, and construction phasing.
New state-of-the-art biopharmaceutical manufacturing facility
Gilbane is providing comprehensive construction management services for Alnylam Pharmaceuticals’ new 200,000 square foot state-of-the-art manufacturing facility that will supply drug substance for RNAi (RNA interference) therapeutics for Alnylam’s clinical and commercial needs. The facility is expected to be operational in 2018 and will initially employ approximately 150 new full-time employees.
Ryan Hutchins, Senior Vice President, Gilbane spoke of the groundbreaking, “The energy and excitement at the event was contagious and it is sure to grow as the new facility develops from a vision into reality. Construction involving biopharmaceutical facilities requires precision, vital documentation, compliance with stringent regulations and a superior commitment to safety. The team we have dedicated to this project have exceptional depth of experience constructing biopharmaceutical facilities. We are truly honored to be a part of Alnylam’s growth in Massachusetts.”